Case ID: f-appx_427/html/0901-01.html
Source: Caselaw Access Project
Author: {"author": "", "license": "Public Domain", "url": "https://static.case.law/"}
Date Created: 2024-08-24T03:29:51.129683

In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc. (now known as Aptalis Pharmatech, Inc.) and Anesta AG, Plaintiffs-Appellants, v. Anchen Pharmaceuticals, Inc. and Anchen, Inc., DefendantsAppellees.
    Nos. 2011-1408, 2011-1410, 2011-1411, 2011-1412.
    United States Court of Appeals, Federal Circuit.
    Aug. 31, 2011.
   ON MOTION

ORDER

Upon consideration of the appellants’ motion to withdraw these appeals, and the motion to revise the official caption,

It Is Ordered That:

(1) The motion to withdraw the appeals is granted. The appeals are dismissed.

(2) The motion to revise the caption is granted. The revised official caption is reflected above.

(3) Each side shall bear its own costs.

(4) Any other pending motions are denied as moot.